GSK plc (LON:GSK) Receives GBX 1,805.83 Consensus Price Target from Analysts

GSK plc (LON:GSK) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is GBX 1,805.83 ($22.73).

Several equities research analysts recently weighed in on the company. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank reduced their target price on GSK from GBX 1,820 ($22.91) to GBX 1,600 ($20.14) and set a “buy” rating for the company in a report on Friday, November 29th.

GSK Stock Down 0.7 %

Shares of GSK stock opened at GBX 1,435 ($18.06) on Friday. The firm has a market cap of £58.23 billion, a price-to-earnings ratio of 23.18, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. GSK has a 52-week low of GBX 1,282.50 ($16.14) and a 52-week high of GBX 1,823.50 ($22.95). The stock has a 50-day simple moving average of GBX 1,367.43 and a 200-day simple moving average of GBX 1,454.89.

GSK (LON:GSK) last posted its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.29) earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, equities research analysts expect that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Transactions at GSK

In other news, insider Jonathan Symonds acquired 1,500 shares of the stock in a transaction dated Friday, December 20th. The shares were acquired at an average cost of GBX 1,315 ($16.55) per share, for a total transaction of £19,725 ($24,826.94). Also, insider Emma Walmsley sold 120,653 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of GBX 1,453 ($18.29), for a total value of £1,753,088.09 ($2,206,530.01). Corporate insiders own 1.61% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.